Related references
Note: Only part of the references are listed.Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
Clinical importance of urinary sodium excretion in acute heart failure
Kevin Damman et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction The CHECK-HF Registry
Hans-Peter Brunner-La Rocca et al.
JACC-HEART FAILURE (2019)
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
M. V. Karg et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION
Marat Fudim et al.
AMERICAN HEART JOURNAL (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
S. Sha et al.
DIABETES OBESITY & METABOLISM (2014)
Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: The results from the DATA-HELP registry
Ewa A. Jankowska et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg et al.
LANCET (2010)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction - Results of the CHARM low-left ventricular ejection fraction trials
JB Young et al.
CIRCULATION (2004)
Share Paper
